Founded in 2021, SafePAS is addressing the urgent global need for faster, reliable and accessible drug detection. Drug Hunter delivers lab-grade results in minutes—faster, 20x cheaper, and more reliable than current options. The technology has already earned the prestigious EUROPOL Innovation Award and completed a successful pilot with the Estonian police, with several law enforcement agencies and strategic partners now in the pipeline.
At the core of the innovation lies a patented combination of capillary electrophoresis, fluorescence detection, and machine learning, built to operate reliably in the field. SafePAS is carving out a unique space in a fast-growing global market for drug testing equipment, valued at €14B and expanding at 5% CAGR.
“Our vision is to bring real-time, accurate drug testing directly to those who need it—police, workplaces, borders, and emergency teams—without waiting on centralized labs,” said CEO and co-founder Jekaterina Mazina. “We’re building tools that help people act on data, not delays.”
The round also underscores PurposeTech’s growing role in supporting HealthTech founders in the region. “SafePAS is setting a new standard in drug testing with a portable, lab-grade device that’s faster, cheaper, and more reliable than anything on the market,” said Zdenek Fred Fous, General Partner at PurposeTech. “With strong early traction, patented tech, and a multimillion-euro EIC grant, they’re well-positioned to lead across sectors—from law enforcement to workplace safety and beyond.”
